IVIG 10% Shows Effectiveness as Rescue Treatment for CIDP Relapses in New Clinical Trial

New clinical trial results indicate that intravenous immunoglobulin (IVIG) 10% demonstrates effectiveness as a rescue treatment for patients experiencing relapses of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The findings suggest a potential role for IVIG 10% in managing CIDP relapses. In addition, it highlights the importance of pharmacist involvement in patient care. The study focused on the use of IVIG 10% as a rescue therapy, specifically for individuals with CIDP who were experiencing a relapse. This suggests IVIG 10% may be a therapeutic option when patients experience a return of symptoms. Furthermore, the trial underscores the need for comprehensive patient management strategies. Pharmacists are considered crucial in the treatment.

Newsflash | Powered by GeneOnline AI
Date: May 2, 2025

Author

Mark Chiang